Evidence map›Paper›PMID 26821018›Full record

ArticleInternational journal of molecular sciences2016

miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites.

Gabriel Rinnerthaler, Hubert Hackl, Simon Peter Gampenrieder, Frank Hamacher, Clemens Hufnagl, Cornelia Hauser-Kronberger, Franz Zehentmayr, Gerd Fastner, Felix Sedlmayer, Brigitte Mlineritsch and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed.

  1. Trial
  2. Article
  3. MECP2 Insufficiency Attenuates RUNX2-Dependent Osteoblast Differentiation via miR-126-3p/DKK1-Mediated Canonical Wnt Signaling Inhibition in Rett Syndrome.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gabriel RinnerthalerIIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. g.rinnerthaler@salk.at.
Hubert HacklDivision of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck 6020, Austria. hubert.hackl@i-med.ac.at.
Simon Peter GampenriederIIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. s.gampenrieder@salk.at.
Frank HamacherIIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. Frank.Hamacher71@gmx.de.
Clemens HufnaglIIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. cl.hufnagl@salk.at.
Cornelia Hauser-KronbergerDepartment of Pathology, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. c.kronberger@salk.at.
Franz ZehentmayrDepartment of Radiotherapy, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. f.zehentmayr@salk.at.
Gerd FastnerDepartment of Radiotherapy, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. g.fastner@salk.at.
Felix SedlmayerDepartment of Radiotherapy, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. f.sedlmayer@salk.at.
Brigitte MlineritschIIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. b.mlineritsch@salk.at.
Richard GreilIIIrd Medical Department with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg 5020, Austria. r.greil@salk.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For quantitative microRNA analyses in formalin-fixed paraffin-embedded (FFPE) tissue, expression levels have to be normalized to endogenous controls. To investigate the most stably-expressed microRNAs in breast cancer and its surrounding tissue, we used tumor samples from primary tumors and from metastatic sites. MiRNA profiling using TaqMan(®) Array Human MicroRNA Cards, enabling quantification of 754 unique human miRNAs, was performed in FFPE specimens from 58 patients with metastatic breast cancer. Forty-two (72%) samples were collected from primary tumors and 16 (28%) from metastases. In a cross-platform analysis of a validation cohort of 32 FFPE samples from patients with early breast cancer genome-wide microRNA expression analysis using SurePrintG3 miRNA (8 × 60 K)(®) microarrays from Agilent(®) was performed. Eleven microRNAs could be detected in all samples analyzed. Based on NormFinder and geNorm stability values and the high correlation (rho ≥ 0.8) with the median of all measured microRNAs, miR-16-5p, miR-29a-3p, miR-126-3p, and miR-222-3p are suitable single gene housekeeper candidates. In the cross-platform validation, 29 human microRNAs were strongly expressed (mean log2-intensity > 10) and 21 of these microRNAs including miR-16-5p and miR-29a-3p were also stably expressed (CV < 5%). Thus, miR-16-5p and miR-29a-3p are both strong housekeeper candidates. Their Normfinder stability values calculated across the primary tumor and metastases subgroup indicate that miR-29a-3p can be considered as the strongest housekeeper in a cohort with mainly samples from primary tumors, whereas miR-16-5p might perform better in a metastatic sample enriched cohort.

Indexed as

Gene ExpressionGenes, EssentialBreast NeoplasmsFemaleGene Expression ProfilingHumansMicroRNAsNeoplasm MetastasisOligonucleotide Array Sequence AnalysisMicroRNAsMIRN16 microRNA, humanMIRN29a microRNA, humanbreast cancercontrolendogenous controlhousekeepermicroRNAmiR-16miR-16-5p

Identifiers

PMID26821018
PMCPMC4783890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.